You are here
Home > RX List

Search RXList.com© Drug Database

Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.

Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.

Alphabetical Listing of drugs

a b c d e f g h i j k l m
n o p q r s t u v w x y z

Description for TissueBlue

TissueBlue (Brilliant Blue G Ophthalmic Solution) 0.025% is a sterile solution of BBG (a dye). Each mL of TissueBlue 0.025% contains BBG 0.25 mg, Polyethylene Glycol 40mg and Buffered Sodium Chloride solution (8.20 mg of sodium chloride, 3.10 mg sodium phosphate dibasic dodecahydrate, 0.30 mg sodium phosphate monobasic dihydrate, water for injection). The pH range of TissueBlue 0.025% Solution is between 7.3 and 7.6.

The drug substance BBG has the chemical name Brilliant Blue G, a molecular weight of 854.02 and has the following chemical structure:

TissueBlue Structural Formula - Illustration

Molecular formula: C47H48N3NaO7S2.

Uses for TissueBlue

TissueBlue 0.025% is indicated to selectively stain the internal limiting membrane (ILM).

Dosage for TissueBlue

TissueBlue 0.025% is carefully injected into the Balanced Salt Solution (BSS)-filled vitreous cavity using a blunt cannula attached to the pre-filled syringe, without allowing the cannula to contact the retina or allowing TissueBlue to get under the retina. Sufficient staining is expected within a few seconds. Following staining, all excess dye should be removed from the vitreous cavity.

HOW SUPPLIED

Dosage Forms And Strengths

TissueBlue (Brilliant Blue G Ophthalmic Solution) 0.025% is a clear, bright blue, single-patient-use ophthalmic solution supplied in 2.25 mL syringes pre-filled to a volume of 0.5 mL.

Storage And Handling

TissueBlue (Brilliant Blue G Ophthalmic Solution), 0.025% is supplied as 0.5 mL of Brilliant Blue G Ophthalmic Solution, 0.025% in a sterile, single-patient-use Luer Lok, 2.25 mL glass syringe, with a grey rubber plunger stopper and tip cap with
polypropylene plunger rod in a pre-formed polypropylene blister pouch sealed with a Tyvek® lid.

NDC 68803-722-05 (One 0.5 mL syringe)
NDC 68803-722-25 (Carton of five 0.5 mL syringes)

TissueBlue 0.025% should be stored at 15°C to 25°C (59°F to 77°F). Protect from light, frost and moisture.

Distributed by: Dutch Ophthalmic, USA. 10 Continental Drive, Bldg 1. Exeter, NH 03833, USA. Phone: 800-75-DUTCH or 603-778-6929 Revised: Apr 2025

Side Effects for TissueBlue

Adverse reactions that have been reported in procedures that included the use of Brilliant Blue G Ophthalmic Solution have often been associated with the surgical procedure. These complications include retinal (retinal break, tear, hemorrhage, and detachment) and cataracts.

Drug Interactions for TissueBlue

No Information provided

Warnings for TissueBlue

Included as part of the PRECAUTIONS section.

Precautions for TissueBlue

Excessive Staining

Excess TissueBlue 0.025% should be removed from the eye immediately after staining.

Use of the Syringe

Make sure the plunger moves smoothly before injecting the solution. Do not use the product if the plunger does not move smoothly to prime the cannula.

Use In Specific Populations

Pregnancy

Risk Summary

There are no available data on the use of TissueBlue 0.025% in pregnant women to inform a drug associated risk. Systemic absorption of TissueBlue 0.025% in humans is expected to be negligible following intravitreal injection and subsequent removal of the drug at the completion of surgical procedures. Due to the negligible systemic exposure, it is not expected that maternal use of TissueBlue 0.025% will result in fetal exposure to the drug.

Adequate animal reproduction studies were not conducted with TissueBlue 0.025%.

Lactation

Risk Summary

No data are available regarding the presence of Brilliant Blue G in human milk after intraocular administration of TissueBlue 0.025%, or the effects on the breastfed infant or the effects on milk production. However, breastfeeding is not expected to result in exposure of the child to Brilliant Blue G due to the expected negligible systemic exposure of BBG in humans following intravitreal injection and subsequent removal of the drug at the completion of surgical procedures.

Pediatric Use

The safety and effectiveness of TissueBlue 0.025% in pediatric patients has not been established.

Geriatric Use

No overall differences in safety or effectiveness were observed between elderly and younger adult patients.

Overdose Information for TissueBlue

No information provided.

Contraindications for TissueBlue

None

Clinical Pharmacology for TissueBlue

Mechanism Of Action

Brilliant Blue G has been shown to selectively stain the ILM, but not the epiretinal membrane nor the retina, making it easier to visualize the membrane for removal, although the exact mechanism of this selectivity has not been elucidated.

Patient Information for TissueBlue

No information provided. Please refer to the WARNINGS AND PRECAUTIONS sections.

From WebMD Logo

Eye Health Resources
  • How Injections Help Slow Geographic Atrophy
  • Overcoming DME: A Guide to Treatment
  • Solutions for Dry Eye Relief in Seniors
Featured Centers
  • What Are the Best PsA Treatments for You?
  • Understanding Biologics
  • 10 Things People With Depression Wish You Knew


RX List

thpxl